Contract research organisation Parexel posted a 26 per cent hike in first quarter revenues to $263m but still failed to meet its own internal sales targets and saw net profits slide.
Disposable bioreactor specialist Wave Biotech AG of Switzerland has been snapped up by its commercial and development partner Sartorius-Stedim for an undisclosed sum.
Clinical research specialist PharmaNet Development Group reported a decline in both sales and earnings for the third quarter but has kept its guidance for the financial year at the same level, albeit excluding an as-yet unresolved impairment charge.
Next year, drug revenues will grow 5 per cent to $820bn according to IMS Health, as the global downturn, patent expiry and flat-lining growth rates in mature markets all make their presence felt.
The US Food and Drug Administration (FDA) has issued a warning letter to Pharmalucence for alleged deviations from current good manufacturing practices (cGMP).
Jubilant Organosys, India's largest custom research and manufacturing services (CRAMS) provider, has reorganised its business in North America in the wake of its recent acquisitions of HollisterStier Laboratories and Draxis Specialty Pharmaceuticals.
India’s Shasun Pharma Solutions is to close its manufacturing facility in Annan, Scotland explaining that the site is being “underused,” according to media reports.
Contracting giant Catalent says its pre-filled syringe facility in Brussels, Belgium has received Food and Drug Administration approval for the manufacture of products for the US market.
AngioChem has posted findings that its lead candidate using its propriety technology for crossing the blood-brain barrier (BBB) is safe and well tolerated.
Isochem will have manufactured ten tonnes of the multi-purpose drug excipient vitamin E TPGS by the end of the year, marking the end of what it says has been a successful first 12 months of commercial scale production.
The NAFDAC has banned 22 firms that it says are involved in the manufacture of fake drugs from ever again selling pharmaceuticals in Nigeria, as part of a countrywide clampdown.
Irish contract developer and service provider Icon is not seeing a slowdown in business from biotechnology firms despite global downturn, according to CEO Peter Gray.
Covance has defied challenging market conditions and posted positive results for the third quarter, with the company believing more major R&D outsourcing contracts are a possibility.
Irish drugmaker Elan has shelved plans to sell its contracting arm EDT in favour of improving the division’s profitability, despite receiving what it describes as “considerable interest” in the unit.
Patheon hopes that a new pharmaceutical development services (PDS) suite at its facility in Whitby, Ontario will complete its “Quick to Clinic” offering and provide a rapid-response means of making solid dosage forms for trials.
Sun Pharmaceutical has posted a strong set of results for the second quarter of fiscal 2009, driven by improved performance by both its Indian branded drug and US generics businesses.
AgilityBio, a division of BioImagene, and Advinus Therapeutics, have teamed up to bolt on imaging services to the latter’s existing preclinical development offering.
French drug giant Sanofi-Aventis has set its sights on developing China as its Asian R&D hub, unveiling plans for a significant expansion of its clinical research unit in Shanghai.
Merck & Co plans to cut 7,200 jobs, joining the growing list of big pharma firms enacting restructuring measures in the face of falling earnings and an uncertain market future.
Increasing bureaucracy in clinical research in the UK is posing a threat to the industry, according to a report published in the British Medical Journal.
The pharmaceutical industry must adapt its processes and strategies to cope with a new, tougher operating environment, according to Stefan Borgas, CEO of Lonza.
Contract drug development company Azopharma Product Development has set up a new business unit to cater for companies wanting to run microdosing or so-called Phase 0 studies.
India’s reputation as a base for quality, low-cost drug manufacture has proved irresistible for yet another big pharma company with Japan’s Eisai unveiling plans for a new production and R&D facility.
Ethex has withdrawn three lots of its generic drug dextroamphetamine sulphate, which is used to treat ADHD and narcolepsy, after analysis revealed that some oversized tablets had been produced.
3M’s drug delivery division and US biotechnology firm VaxInnate have teamed up to develop transdermal influenza vaccine delivery patch in preparation for the anticipated pandemic.
Pfizer and Schering-Plough have both exceeded their earnings estimates, although this was largely underpinned by favourable exchange rates and low expectations.
Welcome to in-pharma technologist’s podcast. In the next three minutes Gareth Macdonald will take you through the top industry headlines this week. Product authenticity dominated the news, with US regulators announcing increased penalties for those convicted...
US FDA approval for Teva’s transdermal fentanyl patch ushers the Israeli generics giant into the potentially lucrative but often problematic chronic pain therapy sector.
Bend Research is offering companies some of the drug delivery formulation expertise and technologies it developed during its 23 year collaboration with Pfizer.
The pharmaceutical industry sometimes seems besieged from all sides at present, and that has implications for contract manufacturers, according to Stefan Borgas, CEO of Lonza, at a recent meeting of the European Fine Chemicals Group (EFCG) in Frankfurt.
Pharmaceutical Profiles of the UK has completed a groundbreaking study that bundles together a number of tests used to decide whether a drug development candidate is worth pursuing into a single clinical trial.
Data analysis may be the next aspect of the drug industry to be outsourced if the new virtual drug development network created by GSK and UK software firm InforSense is any indication.
Covidien hopes that a $100m (€74m) expansion of facilities at its production hub in St Louis, Missouri, US will boost efficiency and cut the time it takes to bring products to market.
